DE69209414D1 - Hirnaktivitätfördernde Zubereitungen - Google Patents

Hirnaktivitätfördernde Zubereitungen

Info

Publication number
DE69209414D1
DE69209414D1 DE69209414T DE69209414T DE69209414D1 DE 69209414 D1 DE69209414 D1 DE 69209414D1 DE 69209414 T DE69209414 T DE 69209414T DE 69209414 T DE69209414 T DE 69209414T DE 69209414 D1 DE69209414 D1 DE 69209414D1
Authority
DE
Germany
Prior art keywords
preparations
brain activity
promote brain
cerebral performance
alleviation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69209414T
Other languages
English (en)
Other versions
DE69209414T2 (de
Inventor
Joachim Bormann
Wolfgang Schatton
Ruediger Koch
Roman Goertelmeyer
Lothar Demisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz and Co GmbH and Co KG
Original Assignee
Merz and Co GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz and Co GmbH and Co KG filed Critical Merz and Co GmbH and Co KG
Publication of DE69209414D1 publication Critical patent/DE69209414D1/de
Application granted granted Critical
Publication of DE69209414T2 publication Critical patent/DE69209414T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69209414T 1991-09-06 1992-09-04 Hirnaktivitätfördernde Zubereitungen Expired - Fee Related DE69209414T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/755,814 US5262162A (en) 1991-09-06 1991-09-06 Cerebral-activating extract

Publications (2)

Publication Number Publication Date
DE69209414D1 true DE69209414D1 (de) 1996-05-02
DE69209414T2 DE69209414T2 (de) 1996-12-05

Family

ID=25040758

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69209414T Expired - Fee Related DE69209414T2 (de) 1991-09-06 1992-09-04 Hirnaktivitätfördernde Zubereitungen

Country Status (11)

Country Link
US (1) US5262162A (de)
EP (1) EP0531155B1 (de)
JP (1) JPH05194247A (de)
KR (1) KR100256452B1 (de)
AT (1) ATE135916T1 (de)
CA (1) CA2077589A1 (de)
DE (1) DE69209414T2 (de)
DK (1) DK0531155T3 (de)
ES (1) ES2086666T3 (de)
GR (1) GR3020121T3 (de)
TW (1) TW217989B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743062B1 (de) * 1995-05-17 2001-08-16 Peter Greither Verfahren zum Herstellen eines Brausepräparats und Brausepräparat
US5747006A (en) * 1997-05-14 1998-05-05 Amway Corporation Skin whitener composition containing acerola cherry fermentate
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DE59706616D1 (de) * 1997-10-27 2002-04-18 Gergely Gerhard Brausezubereitung mit Pflanzenextrakt
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
CA2319318A1 (en) * 1998-01-27 1999-07-29 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
US6184247B1 (en) 1999-05-21 2001-02-06 Amway Corporation Method of increasing cell renewal rate
US6413558B1 (en) 1999-07-19 2002-07-02 The Proctor & Gamble Co. Compositions, kits, and methods for providing and maintaining energy and metal alertness
DE102004041270A1 (de) 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
ES2538088T5 (es) * 2010-08-27 2019-04-17 Finzelberg Gmbh & Co Kg Extractos vegetales de Sideritis y su uso para el aumento de la capacidad cognitiva
AU2014292541B2 (en) 2013-07-14 2018-11-15 Asiros A/S Alkaloid compositions from ribes species to treat conditions assosiated with mitochondrial function or inhibition of PDE4, PDE5 and IKK-Beta
HUE051469T2 (hu) 2014-09-16 2021-03-01 Roar Holding Llc Energiaitalok és egyéb táplálkozási segédanyagok, amelyek agavé alapú szeszes italokból származnak
AU2018323787A1 (en) * 2017-08-28 2020-04-09 Vitality Wellness (Nz) Limited Improvements in IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions
JP2022511759A (ja) 2018-11-26 2022-02-01 ロアー ホールディング エルエルシー 飲料品質を改善する方法
US11839622B1 (en) 2020-01-15 2023-12-12 Randall Lewarchik Consumable nutraceutical composition
WO2023163606A1 (en) * 2022-02-28 2023-08-31 Arepa Ip Limited Bioactives and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR92301E (fr) * 1963-08-09 1968-10-25 Chibret Lab Perfectionnements apportés aux procédés pour l'obtention de glucosides notamment de glucosides d'anthocyanes
FR6760M (de) * 1967-05-30 1969-03-03
EP0092076B1 (de) * 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Lipidhaltige Zusammensetzung für die orale, enterale oder parenterale Ernährung
GB2147911B (en) * 1983-10-14 1987-10-07 Nestle Sa A process for the preparation of fatty substances
FR2583640A1 (fr) * 1985-06-24 1986-12-26 Berdal Pascal Compositions pharmaceutiques a visee vasculotrope et antisclereuse
GB2183635B (en) * 1985-10-11 1990-01-24 Peter Jowett Glyceride ester of gamma-linolenic acid
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
FR2622453A1 (fr) * 1987-11-04 1989-05-05 Vaillant Defresne Laboratoire Composition sous forme de gel transparent contenant des grains ou des particules de plantes fraiches ou seches, son procede de preparation et utilisation en cosmetologie, en pharmacie et en hygiene

Also Published As

Publication number Publication date
EP0531155A1 (de) 1993-03-10
EP0531155B1 (de) 1996-03-27
CA2077589A1 (en) 1993-03-07
ES2086666T3 (es) 1996-07-01
JPH05194247A (ja) 1993-08-03
DK0531155T3 (da) 1996-06-10
GR3020121T3 (en) 1996-08-31
DE69209414T2 (de) 1996-12-05
US5262162A (en) 1993-11-16
KR100256452B1 (ko) 2000-05-15
ATE135916T1 (de) 1996-04-15
TW217989B (de) 1993-12-21

Similar Documents

Publication Publication Date Title
DE69209414D1 (de) Hirnaktivitätfördernde Zubereitungen
Barsky Amplification, somatization, and the somatoform disorders.
Reitz et al. Adoption and the family system: Strategies for treatment.
Turner et al. Depression and disability: The stress process in a chronically strained population.
NO881657D0 (no) Medisinske preparater paa grunnlag av oelmaskekstrakt, fremgangsmaate for fremstilling -derav samt anvendelse av oelmaskekstrakt for fremstilling av kosmetiske preparater og et spesielt oelmaskekstrakt.
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
ATE100322T1 (de) Verwendung von uridin zur behandlung nervoeser stoerungen.
SV1998000138A (es) Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal ref.lea 32408
Caplan Population-oriented psychiatry.
EP0267676A3 (de) Verwendung von 1,3-Di-n-butyl-7-(2-oxypropyl)xanthin zur Behandlung von zerebrovaskulären oder mit zerebraler Senilität assoziierten Störungen, von peripherer Gefässkrankheit und proliferativen Hautkrankheiten
Grandin Brief report: Response to national institutes of health report
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
EP0383171A3 (de) 2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
Gómez-Wong et al. Effects of a prepulse stimulus on the masseteric inhibitory reflex in humans
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
Menon et al. Sertraline and liver toxicity in the elderly.
Dilley et al. Psychological complications of AIDS.
Dawe et al. Effects of a xanthine derivative, oxpentifylline, on certain psychological parameters of behaviour and performance
MY118760A (en) Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae of cyanobacteria
PE37498A1 (es) Composiciones para la prevencion y tratamiento de trastornos gastrointestinales
MY113635A (en) Methods and compositions for the prevention and treatment of gastrointestinal disorders
Gambini et al. Neurofunctional assessment of functional CNS disorders: Neuropsychological characteristics of hemispheric functioning as related to drug treatment in schizophrenia.
Stolyarova et al. Experimental use of selective monoamine oxidase inhibitors in the treatment of parkinsonism patients.
ATE232736T1 (de) Zusammensetzungen zur vorbeugung und behandlung von urogenitalen störungen, die wismut enthalten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee